Immunosuppression and Carcinogenesis: effects of azathioprine on induction of sarcomas by 3-methylcholanthrene. 1977

M De Jong, and M C Coppee, and F De Halleux, and C Deckers, and H Maisin

The effects of Azathioprine (AZA) on the carcinogenesis with 3-Methylcholanthrene (MC) are described. When AZA is given before MC, there is a shortened tumor latency period. When AZA treatment followed MC injection a lengthened latency period was observed. When AZA treatment is given both before and after MC injection, intermediate results were observed. It is concluded that the action of AZA treatment on tumor development depends on the time relationship between this treatment and the injection of the carcinogen. In particular, it is suggested that to obtain an enhancing effect on tumor development, probably by immunosuppression, AZA must be effective at the time or shortly after administration of the carcinogen. When AZA is administered later, an inhibition of tumor development, probably a cytostatic effect becomes prominent.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008748 Methylcholanthrene A carcinogen that is often used in experimental cancer studies. 20-Methylcholanthrene,3-Methylcholanthrene,20 Methylcholanthrene,3 Methylcholanthrene
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001379 Azathioprine An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed) Azathioprine Sodium,Azathioprine Sodium Salt,Azathioprine Sulfate,Azothioprine,Immuran,Imuran,Imurel,Sodium, Azathioprine
D012208 Rhabdomyosarcoma A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9) Rhabdomyosarcomas
D012513 Sarcoma, Experimental Experimentally induced neoplasms of CONNECTIVE TISSUE in animals to provide a model for studying human SARCOMA. EHS Tumor,Sarcoma, Engelbreth-Holm-Swarm,Sarcoma, Jensen,Experimental Sarcoma,Experimental Sarcomas,Sarcomas, Experimental,Engelbreth-Holm-Swarm Sarcoma,Jensen Sarcoma,Sarcoma, Engelbreth Holm Swarm,Tumor, EHS
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

M De Jong, and M C Coppee, and F De Halleux, and C Deckers, and H Maisin
November 1960, Journal of the National Cancer Institute,
M De Jong, and M C Coppee, and F De Halleux, and C Deckers, and H Maisin
January 1970, Journal of the National Cancer Institute,
M De Jong, and M C Coppee, and F De Halleux, and C Deckers, and H Maisin
September 1959, Journal of the National Cancer Institute,
M De Jong, and M C Coppee, and F De Halleux, and C Deckers, and H Maisin
January 1958, Schweizerische Zeitschrift fur Pathologie und Bakteriologie. Revue suisse de pathologie et de bacteriologie,
M De Jong, and M C Coppee, and F De Halleux, and C Deckers, and H Maisin
December 1973, Bulletin of the Chest Disease Research Institute, Kyoto University,
M De Jong, and M C Coppee, and F De Halleux, and C Deckers, and H Maisin
August 1973, Journal of the National Cancer Institute,
M De Jong, and M C Coppee, and F De Halleux, and C Deckers, and H Maisin
July 1970, Surgery,
M De Jong, and M C Coppee, and F De Halleux, and C Deckers, and H Maisin
October 1996, Proceedings of the National Academy of Sciences of the United States of America,
M De Jong, and M C Coppee, and F De Halleux, and C Deckers, and H Maisin
September 2002, Biochemical and biophysical research communications,
M De Jong, and M C Coppee, and F De Halleux, and C Deckers, and H Maisin
January 1971, Journal of the National Cancer Institute,
Copied contents to your clipboard!